Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV)
CUSIP: 004890109
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 38,870,454
- Total 13F shares
- 17,802,633
- Share change
- -4,714,071
- Total reported value
- $21,184,501
- Price per share
- $1.19
- Number of holders
- 52
- Value change
- -$10,332,852
- Number of buys
- 26
- Number of sells
- 39
Quarterly Holders Quick Answers
What is CUSIP 004890109?
CUSIP 004890109 identifies ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 004890109:
Top shareholders of ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Kristina Masson |
3/4/5
|
EVP - Business Operations, Director |
—
class O/S missing
|
2,819,375
|
$19,792,013 | — | 14 Aug 2024 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
3/4/5
|
Company · Director, 10%+ Owner |
21%
|
8,340,508
|
$16,931,231 | — | 31 Mar 2025 | |
| Chione Ltd |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,848,632
|
$16,741,549 | — | 26 Jun 2023 | |
| PERCEPTIVE ADVISORS LLC |
13F
3/4/5
|
Company · 10%+ Owner |
8%
from 3/4/5
|
5,360,858
|
$10,882,542 | — | 31 Mar 2025 | |
| Sands Capital Alternatives, LLC |
13F
|
Company |
5.5%
|
2,122,605
|
$4,308,888 | — | 31 Mar 2025 | |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
888,130
|
$3,863,366 | — | 17 Nov 2022 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
4.9%
|
1,895,519
|
$3,847,904 | — | 31 Mar 2025 | |
| Sands Capital Life Sciences Pulse Fund II, L.P. |
13D/G
|
— |
6.8%
|
2,122,605
|
$2,525,900 | $0 | 30 Jun 2025 | |
| BlackRock, Inc. |
13F
|
Company |
2.4%
|
938,707
|
$1,905,576 | — | 31 Mar 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
2.3%
|
888,130
|
$1,802,904 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.7%
|
674,790
|
$1,369,824 | — | 31 Mar 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
1.2%
|
450,391
|
$914,293 | — | 31 Mar 2025 | |
| ACORN CAPITAL ADVISORS, LLC |
13F
|
Company |
1%
|
405,237
|
$822,632 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.79%
|
306,111
|
$621,578 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.6%
|
232,551
|
$472,079 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.29%
|
111,320
|
$225,980 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.28%
|
109,025
|
$221,321 | — | 31 Mar 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.2%
|
77,900
|
$158,137 | — | 31 Mar 2025 | |
| Rasmus Holm-Jorgensen |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
135,397
mixed-class rows
|
$141,397 | — | 01 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.15%
|
57,519
|
$116,763 | — | 31 Mar 2025 | |
| WEALTHEDGE INVESTMENT ADVISORS, LLC |
13F
|
Company |
0.15%
|
56,467
|
$114,628 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.13%
|
52,100
|
$105,763 | — | 31 Mar 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.11%
|
44,154
|
$89,990 | — | 31 Mar 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.09%
|
35,315
|
$71,690 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.09%
|
35,221
|
$71,499 | — | 31 Mar 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.08%
|
32,698
|
$66,377 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.07%
|
27,699
|
$56,229 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.07%
|
27,635
|
$56,099 | — | 31 Mar 2025 | |
| EXCHANGE TRADED CONCEPTS, LLC |
13F
|
Company |
0.06%
|
23,161
|
$47,017 | — | 31 Mar 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
0.06%
|
22,809
|
$46,302 | — | 31 Mar 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.04%
|
17,381
|
$35,283 | — | 31 Mar 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.04%
|
16,600
|
$33,690 | — | 31 Mar 2025 | |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) |
13F
|
Company |
0.04%
|
15,576
|
$31,619 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.04%
|
14,580
|
$29,597 | — | 31 Mar 2025 | |
| Marex Group plc |
13F
|
Company |
0.04%
|
14,080
|
$28,583 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.03%
|
13,402
|
$27,206 | — | 31 Mar 2025 | |
| PRELUDE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.03%
|
13,067
|
$26,526 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.03%
|
12,888
|
$26,162 | — | 31 Mar 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.03%
|
11,159
|
$22,653 | — | 31 Mar 2025 | |
| AAF Wealth Management, LLC |
13F
|
Company |
0.03%
|
10,678
|
$21,677 | — | 31 Mar 2025 | |
| INTECH INVESTMENT MANAGEMENT LLC |
13F
|
Company |
0.03%
|
10,091
|
$20,485 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.02%
|
8,479
|
$17,213 | — | 31 Mar 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.02%
|
7,090
|
$14,393 | — | 31 Mar 2025 | |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. |
13F
|
Company |
0.02%
|
7,087
|
$14,387 | — | 31 Mar 2025 | |
| China Universal Asset Management Co., Ltd. |
13F
|
Company |
0.02%
|
6,245
|
$12,677 | — | 31 Mar 2025 | |
| Corebridge Financial, Inc. |
13F
|
Company |
0.01%
|
5,787
|
$11,748 | — | 31 Mar 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
3,090
|
$6,273 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
0.01%
|
2,665
|
$5,410 | — | 31 Mar 2025 | |
| NEW YORK STATE COMMON RETIREMENT FUND |
13F
|
Company |
0.01%
|
2,314
|
$4,697 | — | 31 Mar 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0%
|
1,336
|
$2,712 | — | 31 Mar 2025 |
Institutional Holders of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) as of Q2 2025
As of 30 Jun 2025,
Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) was held by
52 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
17,802,633 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., Sands Capital Alternatives, LLC, CITADEL ADVISORS LLC, WELLINGTON MANAGEMENT GROUP LLP, VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, BlackRock, Inc., ACORN CAPITAL ADVISORS, LLC, JACOBS LEVY EQUITY MANAGEMENT, INC, and JANE STREET GROUP, LLC.
This page lists
52
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
60
Q2 2025 holders
52
Holder diff
-8
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.